Substantial doubt about the company's ability to continue as a going concern.
“As of the report date, we do not believe our existing cash and cash equivalents are sufficient to fund our operating and capital expenditure requirements for at least 12 months from the date of issuance of the audited consolidated financial statements included in this Report. Based on our current research and development plans, we expect to have sufficient resources to fund our planned operations into the fourth quarter of 2026. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than expected. No assurance can be given as to whether additional needed financing will be available on terms acceptable to us, if at all. If sufficient funds on acceptable terms are not available when needed, we may be required to suspend or forego certain planned activities. Failure to manage discretionary spending or raise additional financing, as needed, could adversely impact our ability to achieve our intended business objectives and may have an adverse effect on our results of operations and future prospects. These factors raise substantial doubt about our ability to continue as a going concern for the twelve-month period from the date of this filing with the SEC.”View the 10-Q filed Aug 11, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Adagio Medical Holdings, Inc. is seeking approval for a reverse stock split of up to 1-for-1,000 to maintain Nasdaq listing compliance. It previously implemented a 1-for-30 split, with split-adjusted trading beginning November 9, 2026.
Adagio Medical Holdings, Inc. will effect a one-for-thirty (1-for-30) reverse stock split at 5:00 p.m. Eastern Time on November 6, 2026. Shares will begin trading on a split-adjusted basis on The Nasdaq Capital Market when the market opens on November 9, 2026.
Adagio Medical Holdings, Inc. stockholders approved a reverse stock split of common stock at a ratio from 1-for-10 to 1-for-500, inclusive; 13,762,886 shares voted for, 819,231 against and 401 abstained.
Adagio Medical Holdings, Inc. will ask stockholders on October 23, 2026 to approve a reverse stock split from 1-for-10 to 1-for-500, with the Board determining the ratio as a means of regaining Nasdaq minimum bid price compliance.
Adagio Medical Holdings, Inc. reported that a Holder converted $776,111 aggregate principal amount of the Notes into 4,978,869 shares of Common Stock at Alternate Conversion Prices ranging from $0.1265 to $0.1618 per share.
Adagio Medical Holdings, Inc. asks stockholders to authorize a reverse stock split from 1-for-10 to 1-for-500, allowing discretionary selection of the ratio or declination. The proposal seeks to address Nasdaq minimum bid price and stockholders’ equity deficiencies.
Adagio Medical Holdings, Inc. initiated a strategic alternatives review and will reduce its workforce by 25 of 43 full-time employees effective September 23, 2026, estimating approximately $1.3 million of cash expenditures.
